Avoid common mistakes on your manuscript.
Correction to: Infect Dis Ther (2024) 13:57–78 https://doi.org/10.1007/s40121-023-00896-w
Copyright owner of GSK stated that its trademark “AS03” has been used in this article and they insist to remove it. Hence, it is removed. Original article is updated.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Wynne, C., Balgos, A., Li, J. et al. Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies. Infect Dis Ther 13, 1723–1724 (2024). https://doi.org/10.1007/s40121-024-00998-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40121-024-00998-z